Senate Inquiry: Interim Findings on Peptides
The Senate inquiry into complementary medicines releases interim findings with direct implications for peptide regulation and consumer protection in Australia.
The Senate Community Affairs References Committee has released interim findings from its inquiry into complementary medicines, with significant attention devoted to the regulation of peptide products sold to Australian consumers.
Key Findings
The interim report, tabled in May 2026, identifies “regulatory gaps” in how peptide products are classified and marketed in Australia. The committee found that the current framework, which distinguishes sharply between therapeutic goods and research chemicals, is being exploited by vendors who market products under the research-use banner while targeting health-conscious consumers.
“The committee is concerned that the distinction between research chemicals and therapeutic goods is not being maintained in practice,” the report states. “Consumers are purchasing products with the expectation of health benefits that have not been evaluated by the TGA.”
The report specifically highlights online sales platforms where peptide products are listed alongside fitness supplements and anti-ageing products, creating what the committee describes as “an implied therapeutic context.”
Witness Testimony
The inquiry heard from 43 witnesses across six public hearings in Canberra, Sydney, and Melbourne. Key testimony came from:
- TGA officials who acknowledged that enforcement resources are stretched thin, particularly for online sales
- Representatives from NATA who described inconsistent testing standards across peptide suppliers
- Consumer advocacy groups who presented case studies of adverse events potentially linked to unregulated peptide products
- Industry representatives who argued that over-regulation could harm legitimate research supply chains
One striking exchange came when Senator [name redacted for publication] asked a TGA representative how many dedicated staff the agency has for monitoring online peptide sales. The answer: fewer than five full-time equivalent positions nationally.
Recommendations
The interim report makes several preliminary recommendations:
- The TGA should develop specific guidance for peptide products that sit on the boundary between research chemicals and therapeutic goods
- Online marketplace operators should be required to verify that peptide sellers hold appropriate licences
- A national advertising standards review for peptide marketing should be conducted
- State and federal enforcement coordination should be formalised through a standing working group
The committee stopped short of recommending reclassification of all peptides as therapeutic goods, acknowledging concerns from the research sector about the impact on legitimate procurement.
Industry Reaction
The Australian complementary medicines industry has broadly welcomed the inquiry’s focus, while expressing concern about potential regulatory overreach. The Complementary Medicines Australia (CMA) industry body said it supported “proportionate regulation that protects consumers without constraining legitimate research.”
Research institutions have flagged the potential for unintended consequences if any future legislative changes affect the import and procurement of research-grade peptides.
What Happens Next
The committee is expected to deliver its final report by September 2026. Submissions are open until July 31. The final recommendations will inform whether the government pursues legislative amendments to the Therapeutic Goods Act or opts for administrative changes through TGA guidance.
Stakeholders on all sides should prepare for a period of regulatory uncertainty as the inquiry progresses.
Sources
- Parliament of Australia — Senate Community Affairs References Committee — Inquiry into complementary medicines and peptide regulation
- TGA — Role of the TGA — TGA regulatory responsibilities for therapeutic goods
- National Association of Testing Authorities (NATA) — Laboratory accreditation and testing standards
- Complementary Medicines Australia (CMA) — Industry body for complementary medicines sector
- Therapeutic Goods Act 1989 — Primary legislation governing therapeutic goods regulation
For educational purposes only. This content is informational and reflects publicly reported developments. It is not legal, medical, or regulatory advice. Consult a qualified professional for compliance questions.